Cargando…
Pretreatment neutrophil-to-lymphocyte ratio predicts treatment efficacy and prognosis of cytotoxic anticancer drugs, molecular targeted drugs, and immune checkpoint inhibitors in patients with advanced non-small cell lung cancer
BACKGROUND: Neutrophil-to-lymphocyte ratio (NLR) has recently attracted attention as a prognostic predictor in patients with non-small cell lung cancer (NSCLC) who receive immune checkpoint inhibitors (ICIs). However, the utility of NLR in relation to cytotoxic anticancer drugs or molecular targeted...
Autores principales: | Ishihara, Masashi, Ochiai, Ryosuke, Haruyama, Terunobu, Sakamoto, Takahiko, Tanzawa, Shigeru, Honda, Takeshi, Ota, Shuji, Ichikawa, Yasuko, Ishida, Tsuyoshi, Watanabe, Kiyotaka, Seki, Nobuhiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867774/ https://www.ncbi.nlm.nih.gov/pubmed/33569306 http://dx.doi.org/10.21037/tlcr-20-777 |
Ejemplares similares
-
Which is better, EGFR-TKI mono or combination for non-small cell lung cancer with mutated EGFR?
por: Tanzawa, Shigeru, et al.
Publicado: (2019) -
Promising Combination Therapy with Bevacizumab and Erlotinib in an EGFR-Mutated NSCLC Patient with MET Amplification Who Showed Intrinsic Resistance to Initial EGFR-TKI Therapy
por: Seki, Nobuhiko, et al.
Publicado: (2019) -
Need for Flexible Adjustment of the Treatment Schedule for Aprepitant Administration against Erlotinib-Induced Refractory Pruritus and Skin Rush
por: Seki, Nobuhiko, et al.
Publicado: (2019) -
A Case of Lung Adenocarcinoma with Marked Improvement of Pulmonary Lymphangitic Carcinomatosis by Adding Bevacizumab to Cisplatin and Pemetrexed
por: Natsume, Maika, et al.
Publicado: (2017) -
A Case of Paraneoplastic Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome Improved by Chemotherapy
por: Sakamoto, Takahiko, et al.
Publicado: (2017)